Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $39.75.

A number of brokerages have recently issued reports on GMAB. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Truist Financial reissued a “buy” rating and set a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. HC Wainwright increased their price target on Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th.

Institutional Trading of Genmab A/S

Several hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC lifted its position in shares of Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares during the period. Brown Brothers Harriman & Co. increased its stake in Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares in the last quarter. Community Bank N.A. acquired a new position in shares of Genmab A/S during the third quarter valued at about $47,000. Cromwell Holdings LLC boosted its position in shares of Genmab A/S by 136.3% during the 3rd quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after purchasing an additional 883 shares in the last quarter. Finally, Headlands Technologies LLC grew its stake in shares of Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after buying an additional 1,464 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Up 1.1%

Shares of Genmab A/S stock opened at $32.02 on Friday. The stock has a market cap of $20.57 billion, a price-to-earnings ratio of 13.63, a P/E/G ratio of 1.65 and a beta of 0.90. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $33.65. The company’s fifty day moving average is $30.78 and its 200 day moving average is $25.83.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. As a group, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.